Celgene financials

Celgene Revenue

Celgene revenue was $15.28 b in FY, 2018 which is a 17.5% year over year increase from the previous period.

Embed Graph

Founding Date	1986

Celgene is a subsidiary of Bristol-Myers Squibb

Embed Graph

Celgene revenue breakdown by business segment: 10.5% from Inflammation & Immunology, 89.4% from Hematology / Oncology and 0.1% from Other

Celgene revenue breakdown by geographic segment: 34.4% from International and 65.6% from U.S.

USD	FY, 2016	FY, 2017	FY, 2018
Revenue	11.2b	13.0b	15.3b
Revenue growth, %	21%	16%	18%
Cost of goods sold	438.0m	461.0m	587.0m
Gross profit	10.8b	12.5b	14.7b
Gross profit Margin, %	96%	96%	96%
R&D expense	4.5b	5.9b	5.7b
General and administrative expense	2.7b	2.9b	3.3b
Operating expense total	7.6b	7.8b	9.5b
Depreciation and amortization	459.0m	329.0m	468.0m
EBIT	3.2b	4.7b	5.2b
EBIT margin, %	28%	36%	34%
Interest expense	500.1m	522.0m	741.0m
Pre tax profit	2.4b	4.3b	4.8b
Income tax expense	373.3m	1.4b	786.0m
Net Income	2.0b	2.9b	4.0b
EPS	2.5	3.6	5.5

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019
Revenue	3.0b	3.3b	3.3b	3.5b	3.8b	3.9b	4.0b	4.4b	4.5b
Cost of goods sold	113.0m	111.0m	118.0m	135.0m	126.0m	157.0m	140.0m	151.0m	167.0m
Gross profit	2.8b	3.2b	3.2b	3.4b	3.7b	3.7b	3.9b	4.2b	4.4b
Gross profit Margin, %	96%	97%	96%	96%	97%	96%	97%	97%	96%
R&D expense	995.0m	835.0m	1.3b	2.2b	1.3b	1.1b	1.2b	1.1b	1.2b
General and administrative expense	620.0m	939.0m	608.0m	864.0m	790.0m	746.0m	773.0m	793.0m	781.0m
Operating expense total	1.7b	1.8b	2.1b	3.2b	2.2b	2.1b	2.2b	2.1b	2.1b
Depreciation and amortization	82.0m	88.0m	80.0m	87.0m	127.0m	127.0m	109.0m	109.0m	109.0m
EBIT	1.1b	1.3b	1.1b	218.0m	1.5b	1.7b	1.7b	2.1b	2.3b
EBIT margin, %	38%	40%	33%	6%	39%	43%	42%	48%	50%
Interest expense	127.0m	126.0m	127.0m	166.0m	192.0m	193.0m	192.0m	192.0m	190.0m
Pre tax profit	1.0b	1.1b	991.0m	1.0b	1.3b	1.4b	1.8b	1.8b	1.9b
Income tax expense	84.0m	69.0m	3.0m	184.0m	262.0m	296.0m	269.0m	250.0m	226.0m
Net Income	941.0m	1.1b	988.0m	846.0m	1.0b	1.1b	1.5b	1.6b	1.7b
EPS	1.2	1.3	1.2	1.1	1.4	1.5	2.1	2.2	2.3

USD	FY, 2016	FY, 2017	FY, 2018
Cash	6.2b	7.0b	4.2b
Accounts Receivable	1.6b	1.9b	2.1b
Inventories	497.9m	541.0m	458.0m
Current Assets	10.9b	14.9b	9.1b
PP&E	929.8m	1.1b	1.4b
Goodwill	4.9b	4.9b	8.0b
Total Assets	28.1b	30.1b	35.5b
Accounts Payable	247.1m	305.0m	418.0m
Short-term debt	500.7m		501.0m
Current Liabilities	3.0b	3.0b	4.1b
Long-term debt	137.9b	15.8b	19.8b
Total Debt	138.4b	15.8b	20.3b
Total Liabilities	21.5b	23.2b	29.3b
Common Stock	9.5m	10.0m	10.0m
Preferred Stock
Additional Paid-in Capital	12.4b	13.8b	15.0b
Retained Earnings	10.1b	13.1b	17.6b
Total Equity	6.6b	6.9b	6.2b
Debt to Equity Ratio	21 x	2.3 x	3.3 x
Debt to Assets Ratio	4.9 x	0.5 x	0.6 x
Financial Leverage	4.3 x	4.4 x	5.8 x

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019
Cash	5.3b	6.7b	5.5b	2.8b	1.5b	2.5b	5.4b	7.2b	9.6b
Accounts Receivable	1.6b	1.7b	1.8b	2.0b	2.1b	2.1b	2.3b	2.5b	2.4b
Inventories	509.0m	533.0m	537.0m	536.0m	555.0m	510.0m	442.0m	464.0m	451.0m
Current Assets	11.6b	13.1b	14.8b	7.9b	6.9b	7.8b	11.0b	12.7b	14.5b
PP&E	958.0m	989.0m	1.0b	1.3b	1.3b	1.3b	1.4b	1.4b	1.4b
Goodwill	4.9b	4.9b	4.9b	8.0b	8.0b	8.0b	8.0b	8.0b	8.0b
Total Assets	28.8b	30.3b	31.7b	34.6b	33.4b	34.2b	37.6b	39.2b	41.4b
Accounts Payable	240.0m	272.0m	263.0m	320.0m	294.0m	292.0m	340.0m	327.0m	421.0m
Short-term debt	500.0m	500.0m	1.4b		1.5b	502.0m	500.0m		1.5b
Current Liabilities	2.6b	3.2b	4.0b	3.1b	4.5b	3.7b	4.0b	3.7b	5.0b
Long-term debt	13.8b	13.8b	12.9b	20.3b	19.8b	19.7b	19.8b	19.8b	18.3b
Total Debt	14.3b	14.3b	14.3b	20.3b	21.3b	20.2b	20.3b	19.8b	19.8b
Total Liabilities	21.2b	21.9b	21.9b	29.4b	30.0b	29.4b	29.5b	29.1b	29.3b
Common Stock	10.0m	10.0m	10.0m	10.0m	10.0m	10.0m	10.0m	10.0m	10.0m
Additional Paid-in Capital	12.7b	13.2b	13.6b	14.1b	13.8b	14.8b	15.4b	15.8b	16.1b
Retained Earnings	11.0b	12.1b	13.1b	14.4b	15.4b	16.5b	19.1b	20.7b	22.4b
Total Equity	7.6b	8.4b	9.9b	5.2b	3.4b	4.9b	8.2b	10.1b	12.1b
Debt to Equity Ratio	1.9 x	1.7 x	1.4 x	3.9 x	6.2 x	4.2 x	2.5 x	2 x	1.6 x
Debt to Assets Ratio	0.5 x	0.5 x	0.4 x	0.6 x	0.6 x	0.6 x	0.5 x	0.5 x	0.5 x
Financial Leverage	3.8 x	3.6 x	3.2 x	6.7 x	9.8 x	7 x	4.6 x	3.9 x	3.4 x

USD	FY, 2016	FY, 2017	FY, 2018
Net Income	2.0b	2.9b	4.0b
Depreciation and Amortization	504.7m	471.0m	635.0m
Accounts Receivable	(222.4m)	(236.0m)	(178.0m)
Inventories	(55.3m)	(42.0m)	82.0m
Accounts Payable	618.9m	273.0m	290.0m
Cash From Operating Activities	4.0b	5.2b	5.2b
Purchases of PP&E	(236.2m)	(279.0m)	(330.0m)
Cash From Investing Activities	(1.0b)	(2.9b)	(6.4b)
Short-term Borrowings	(100.3m)		(5.7b)
Long-term Borrowings		(1.9b)
Cash From Financing Activities	(1.6b)	(1.6b)	(1.5b)
Net Change in Cash	1.3b	843.0m	(2.8b)
Interest Paid	527.2m	539.0m	689.0m
Income Taxes Paid	373.0m	475.0m	1.2b

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019
Net Income	941.0m	2.0b	3.0b	846.0m	1.9b	3.0b	1.5b	3.1b	4.8b
Depreciation and Amortization	121.0m	240.0m	355.0m	126.0m	296.0m	465.0m	157.0m	315.0m	486.0m
Accounts Receivable	17.0m	(75.0m)	(139.0m)	(47.0m)	(157.0m)	(225.0m)	(271.0m)	(385.0m)	(331.0m)
Inventories	(10.0m)	(32.0m)	(37.0m)	6.0m	(14.0m)	31.0m	16.0m	(5.0m)	7.0m
Accounts Payable	(365.0m)	219.0m	28.0m	(219.0m)	(144.0m)	(66.0m)	(28.0m)	71.0m	84.0m
Cash From Operating Activities	853.0m	2.5b	3.6b	(325.0m)	904.0m	2.8b	1.5b	3.6b	5.8b
Purchases of PP&E	(62.0m)	(132.0m)	(176.0m)	(88.0m)	(168.0m)	(232.0m)	(69.0m)	(129.0m)	(197.0m)
Cash From Investing Activities	(1.7b)	(1.6b)	(4.0b)	(5.7b)	(5.8b)	(5.8b)	(295.0m)	(338.0m)	(201.0m)
Short-term Borrowings			(500.0m)	(1.8b)	(3.9b)	(5.7b)
Long-term Borrowings								(500.0m)	(500.0m)
Cash From Financing Activities	(109.0m)	(424.0m)	(292.0m)	1.8b	(643.0m)	(1.6b)	26.0m	(321.0m)	(219.0m)
Net Change in Cash	(897.0m)	490.0m	(659.0m)	(4.2b)	(5.5b)	(4.5b)	1.2b	3.0b	5.4b
Interest Paid	198.0m	262.0m	461.0m	190.0m	300.0m	581.0m	281.0m	390.0m	671.0m
Income Taxes Paid	128.0m	333.0m	450.0m	387.0m	786.0m	974.0m	275.0m	331.0m	503.0m

	FY, 2016	FY, 2017	FY, 2018
Active Clinical Studies	52
Filed Trials Products (Acute Myeloid Leukemia)	2	3	3
Filed Trials Products (Inflammation and Immunology)	2	2	2
Filed Trials Products (Lymphoma)	4	6	6
Filed Trials Products (Multiple Myeloma)	4	5	5
Filed Trials Products (Myelodysplastic Syndromes)	2	2	2
Filed Trials Products (Solid Tumors)	4	4	4
Phase I Trials Products (Acute Myeloid Leukemia)	3	2	3
Phase I Trials Products (Cellular Therapies)	2
Phase I Trials Products (Chronic Lymphocytic Leukemia)	2	1
Phase I Trials Products (Inflammation and Immunology)	3	3	3
Phase I Trials Products (Lymphoma)	5	5	5
Phase I Trials Products (Multiple Myeloma)	6	4	4
Phase I Trials Products (Myelodysplastic Syndromes)	1		1
Phase I Trials Products (Solid Tumors)	4	5	3
Phase I/II Trials Products (Chronic Lymphocytic Leukemia)		1	1
Phase I/II Trials Products (Lymphoma)		1	1
Phase I/II Trials Products (Multiple Myeloma)			1
Phase II Trials Products (Acute Myeloid Leukemia)	1	1
Phase II Trials Products (Cellular Therapies)	2
Phase II Trials Products (Inflammation and Immunology)	6	6	3
Phase II Trials Products (Multiple Myeloma)		1	1
Phase II Trials Products (Myelodysplastic Syndromes)	2	2	1
Phase II Trials Products (Myelofibrosis)		1	1
Phase II Trials Products (Solid Tumors)	3	3
Phase III Trials Products (Acute Myeloid Leukemia)	1	1	1
Phase III Trials Products (Beta Thalassemia)	1	1	1
Phase III Trials Products (Inflammation and Immunology)	5	2	4
Phase III Trials Products (Lymphoma)	4	3	3
Phase III Trials Products (Myelodysplastic Syndromes)	2	2	2
Phase III Trials Products (Solid Tumors)	1	1	4